Zevalin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND High-dose chemotherapy combined with autologous stem-cell transplantation (ASCT) is the standard therapy for… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
2008
2008
Allogeneic SCT is an effective therapy for lymphoma. Reduced-intensity conditioning (RIC) reduces non-relapse mortality (NRM… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2007
2007
In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients… (More)
  • table 5
Is this relevant?
2006
2006
To evaluate whether 89Zr can be used as a PET surrogate label for quantification of 90Y-ibritumomab tiuxetan (90Y-Zevalin… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2003
Review
2003
90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US… (More)
Is this relevant?
Review
2002
Review
2002
Conjugated antibodies have been in clinical trials for over 30 years. Immunotoxins, chemotherapy conjugates and… (More)
Is this relevant?
2002
2002
BACKGROUND Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
UNLABELLED Radiation dosimetry studies were performed in patients with non-Hodgkin's lymphoma (NHL) treated with 90Y Zevalin… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to normal organs… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
1999
Review
1999
Approximately 55,400 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed each year, with the overall prevalence of the… (More)
Is this relevant?